Show simple item record

dc.contributor.authorGutierrez Stampa, María Angeles
dc.contributor.authorAguilar Gama, Vanessa
dc.contributor.authorSarasqueta Eizaguirre, Cristina
dc.contributor.authorCubiella, Joaquín
dc.contributor.authorPortillo Villares, María Isabel
dc.contributor.authorBujanda Fernández de Pierola, Luis ORCID
dc.date.accessioned2020-10-02T11:56:23Z
dc.date.available2020-10-02T11:56:23Z
dc.date.issued2020-08-25
dc.identifier.citationCancers 12(9) : (2020) // Article ID 2412es_ES
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/10810/46366
dc.description.abstractPopulation screening has improved early diagnosis of colorectal cancer (CRC). Nonetheless, most cases are diagnosed in symptomatic patients. Faecal immunochemical testing has been recommended for assessing patients with lower gastrointestinal symptoms, but whether it improves patient survival is unknown. Our objective was to compare CRC survival in 50- to 69-year-olds between asymptomatic screen-detected patients and symptomatic patients by route to diagnosis. Methods: We identified all cases of CRC diagnosed in 50-to 69-year-olds between 2009 and 2016, in Donostialdea (Gipuzkoa, Spain). Three groups were created: 1-screen-detected CRC; 2-CRC detected in symptomatic patients after a positive faecal immunochemical test(FIT); and 3-CRC detected in symptomatic patients without a FIT or after a negative result. We analysed survival using the Kaplan-Meier method and log-rank tests. Results: Of 930 patients diagnosed with CRC, 433 cases were detected through screening and 497 in symptomatic patients, 7.9% after a positive FIT and 45.5% by other means. The 3-year CRC survival was significantly lower in group 3 (69.5%) than groups 1 (93%; p = 0.007) or 2 (87.5%; p = 0.02). The risk of death was lower in groups 1 (HR 0.42, 95% CI 0.30–0.58) and 2 (HR 0.51; 95% CI 0.29–0.87). Conclusion: Half of CRC cases in 50- to 69-year-olds are diagnosed outside screening. Use of the FIT as a diagnostic strategy in symptomatic patients may improve survival.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.subjectcolorectal canceres_ES
dc.subjectfaecal immunochemical testes_ES
dc.subjectsurvivales_ES
dc.titleColorectal Cancer Survival in 50- to 69-Year-Olds after Introducing the Faecal Immunochemical Testes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2020-09-25T13:28:50Z
dc.rights.holder2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/2072-6694/12/9/2412es_ES
dc.identifier.doi10.3390/cancers12092412
dc.departamentoesMedicina
dc.departamentoeuMedikuntza


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).